ArticleDiscovery medicine2013
Advances in the development of vaccines for Alzheimer's disease.
Article in Discovery medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments.Journal of neurology · 2017Pooled it
- Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid β.International journal of molecular sciences · 2023Review
- Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research.Journal of Alzheimer's disease : JAD · 2021Review
- Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia.Cardiology and therapy · 2020Review
- Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.International journal of molecular sciences · 2020Review
- The Impact of Natural Compounds on S-Shaped Aβ42 Fibril: From Molecular Docking to Biophysical Characterization.International journal of molecular sciences · 2020Article
- Early active immunization with AβNeural regeneration research · 2020Article
- Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding.Journal of chemical theory and computation · 2019Article
- Vaccination against atherosclerosis.Current opinion in immunology · 2019Review
- The troubling story of blood-driven dementias.Molecular psychiatry · 2019Article
- Postexposure Effects of Vaccines on Infectious Diseases.Epidemiologic reviews · 2019Review
- Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease.Current Alzheimer research · 2019Article
- Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.Journal of neuroimmunology · 2018Article
- A clinically applicable adjuvant for an atherosclerosis vaccine in mice.European journal of immunology · 2018Article
- Intracellular tracing of amyloid vaccines through direct fluorescent labelling.Scientific reports · 2018Article
- Gamma Band Neural Stimulation in Humans and the Promise of a New Modality to Prevent and Treat Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Article
- Vanillic acid attenuates AβScientific reports · 2017Article
- Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.Scientific reports · 2016Article
- Genomics of Alzheimer Disease: A Review.JAMA neurology · 2016Review
- Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging.Journal of Alzheimer's disease : JAD · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
One of the challenges of our society is to find a treatment or cure for Alzheimer's disease (AD). AD is the leading form of age-related dementia and with the increase of life expectancy worldwide, the social and economic burden from this disease will increase dramatically. It is a progressive and, in regard to clinical scores, a highly variable disease. AD pathogenesis has been associated with the accumulation, aggregation, and deposition of amyloid beta (Abeta) peptides in the brain. Hallmarks of AD are the amyloid plaques consisting of fibrillar Abeta and neurofibrillary tangles which are intracellular fibrils of hyperphosphorylated tau protein that develop later in this disease. The amyloid cascade hypothesis postulates that Abeta deposition is an initial event in the multifactorial pathogenesis and Abeta deposition may precede AD symptoms in some patients by at least 20 years. Amyloid beta therapy with active and passive immunizations against Abeta has a high possibility to be effective in removing Abeta from brain and might thus prevent the downstream pathology. Since 2000 a number of clinical trials for AD immunotherapy have started, have failed, and are continuing to be pursued. This article will review these clinical trials and ongoing research in this regard.
Indexed as
Identifiers
23725605PMC3696351W1786559844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.